New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™ Test
November 20, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Present at 2020 San Antonio Breast Cancer Virtual Symposium
November 17, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Lawsuit for Investors in Progenity, Inc. (NASDAQ: PROG) shares announced by Shareholders Foundation
November 17, 2020 07:10 ET
|
Shareholders Foundation, Inc.
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: PROG shares. Investors, who purchased shares...
Progenity to Host Preeclampsia Virtual R&D Day on November 20, 2020
November 13, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Encouraging Preclinical Data Supporting the Potential of the Company’s Oral Drug Delivery System in Targeting the Colon
November 06, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update
November 03, 2020 08:43 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Presents Data from Award-Winning Abstract on Novel Ingestible Lab-in-a-Capsule at American College of Gastroenterology (ACG) 2020 Virtual Annual Meeting
October 27, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
FINAL DEADLINE ALERT: ROSEN, A LEADING AND RANKED FIRM, Reminds Progenity, Inc. Investors of Important October 27 Deadline in Securities Class Action – PROG
October 24, 2020 10:00 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 24, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and/or traceable to the...
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Progenity, Inc. and Encourages Investors to Contact the Firm
October 20, 2020 17:00 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the...
DEADLINE ALERT for BAK and PROG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
October 19, 2020 12:18 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Oct. 19, 2020 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...